Donor Kidney With Renal Cell Carcinoma Successfully Treated With Radiofrequency Ablation: A Case Report

Christensen, Stina; Hansen, Jesper Melchior

doi:10.1016/j.transproceed.2015.10.039

Cited by 9 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60,61 Conservative treatment by partial surgery or percutaneous ablation should be preferred if the tumor volume, location, and transplant function allow it, according to the French recommendations of the Transplantation Committee of the French Association of Urology. 60 It can also be practiced with multiple probe-needles approaches or multiple ablative sessions in larger lesions, 20,41,43,62,63 such as in our study, with good technical success. However, partial nephrectomy, associated with better disease-free survival and local tumor progression rates, can be preferred in lesions >3 cm, 64 according to Lezzi et al 20 Active surveillance can also be a safe alternative and proposed for patients with small renal masses.…”

Section: Discussionmentioning

confidence: 67%

“…40 Moreover, we do not report significant (grades 3, 4, or 5) periprocedural complications, per the results of Guleryuz et al, who report no complication in their series of 14 ablations. 40 Lezzi et al 20 reported 7 postprocedural complications (11.1%) (4 cases of injury of the genitofemoral nerve or superficial iliopsoas layers, SIR class A-B, CTCAE grade 2, 34,41,42 2 cases of cutaneous urinary fistula treated with antibiotics and surgical management, SIR class C-D, CTCAE grade 3, 34,43 and 1 postablation syndrome (SIR class A-B, CTCAE grade 3). 9…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Thermoablative Treatment of De Novo Tumor in Kidney Allograft

Bodard,

Boudhabhay,

Dariane

et al. 2023

Transplantation

View full text Add to dashboard Cite

Background. The overall cancer risk increases in transplant patients, including in kidney allografts. This study aimed to analyze the outcome of patients with kidney allograft malignant tumors who underwent percutaneous thermal ablation. Methods. We included 26 renal allograft tumors, including 7 clear-cell renal cell carcinoma (RCCs), 16 papillary RCCs, 1 clear-cell papillary RCC, and 2 tubulocystic RCCs, treated in 19 ablation sessions. Outcomes of thermal ablation therapy were assessed, including technical success, adverse events, local tumor progression, development of metastases, survival after thermal ablation, and changes in renal function. Results. Success rate was achieved in all ablation sessions (primary success rate: 96%; secondary success rate: 100%). No adverse events were observed in grades 3, 4, or 5. The median follow-up period was of 34 mo (15–69 mo). Two patients died during follow-up from a cause independent of renal cancer. The median decrease in estimated glomerular filtration rate 1 y after procedure was −4 (interquartile range, −7 to 0) mL/min/1.73 m2. One patient returned to dialysis within the year of the procedure. Conclusions. Percutaneous thermal ablation shows convincing results for treating malignant renal graft tumors and should be a useful treatment option. The shorter hospitalization time, the advantage of avoiding a potentially challenging dissection of the transplant, and the excellent preservation of allograft function appear encouraging to extend this indication.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Thermoablative Treatment of De Novo Tumor in Kidney Allograft

Bodard,

Boudhabhay,

Dariane

et al. 2023

Transplantation

View full text Add to dashboard Cite

show abstract

“…More recently, positive outcomes obtained with NSS have cautiously allowed to extend indications for conservative therapeutic options also to patients with papillary carcinoma[66,67]. We detected several reports in the literature describing successful ablation of papillary lesions in the renal allograft[18,20,23,25,30,38-41,43,44]. Therefore our review further supports the use of AT in recipients with papillary carcinoma as current literature showed similar primary treatment failure, secondary treatment failure, recurrence, graft survival, and disease-free survival for papillary, clear cell, and chromophobe RCC.…”

Section: Discussionmentioning

confidence: 99%

Systematic review of ablative therapy for the treatment of renal allograft neoplasms

Favi

Raison

Ambrogi

et al. 2019

WJCC

View full text Add to dashboard Cite

BACKGROUNDTo date, there are no guidelines on the treatment of solid neoplasms in the transplanted kidney. Historically, allograft nephrectomy has been considered the only reasonable option. More recently, nephron-sparing surgery (NSS) and ablative therapy (AT) have been proposed as alternative procedures in selected cases.AIMTo review outcomes of AT for the treatment of renal allograft tumours.METHODSWe conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 Checklist. PubMed was searched in March 2019 without time restrictions for all papers reporting on radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) of solid tumours of the kidney allograft. Only original manuscripts describing actual cases and edited in English were considered. All relevant articles were accessed in full text. Additional searches included all pertinent references. Selected studies were also assessed for methodological quality using a tool based on a modification of the Newcastle Ottawa scale. Data on recipient characteristics, transplant characteristics, disease characteristics, treatment protocols, and treatment outcomes were extracted and analysed. Given the nature and the quality of the studies available (mostly retrospective case reports and small retrospective uncontrolled case series), a descriptive summary was provided.RESULTSTwenty-eight relevant studies were selected describing a total of 100 AT procedures in 92 patients. Recipient age at diagnosis ranged from 21 to 71 years whereas time from transplant to diagnosis ranged from 0.1 to 312 mo. Most of the neoplasms were asymptomatic and diagnosed incidentally during imaging carried out for screening purposes or for other clinical reasons. Preferred diagnostic modality was Doppler-ultrasound scan followed by computed tomography scan, and magnetic resonance imaging. Main tumour types were: papillary renal cell carcinoma (RCC) and clear cell RCC. Maximal tumour diameter ranged from 5 to 55 mm. The vast majority of neoplasms were T1a N0 M0 with only 2 lesions staged T1b N0 M0. Neoplasms were managed by RFA (n = 78), CA (n = 15), MWA (n = 3), HIFU (n = 3), and IRE (n = 1). Overall, 3 episodes of primary treatment failure were reported. A single case of recurrence was identified. Follow-up ranged from 1 to 81 mo. No cancer-related deaths were observed. Complication rate was extremely low (mostly < 10%). Graft function remained stable in the majority of recipients. Due to the limited sample size, no clear benefit of a single procedure over the other ones could be demonstrated.CONCLUSIONAT for renal allograft neoplasms represents a promising alternative to radical nephrectomy and NSS in carefully selected patients. Properly designed clinical trials are needed to validate this therapeutic approach.

show abstract

“…Recently, the use of RF or cryoablation with an ultrasound guide has been described in the literature in patients unfit for surgery, which included 10 tumors smaller than 4 cm with a mean postinterventional observation period of 10.5 months. No complications were reported in these cases.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, partial nephrectomy (PN) and percutaneous (ultrasound‐ or computed tomography [CT]‐guided thermal ablations) techniques have expanded the range of nephron‐sparing approaches also in this field. Scanned data exist in the literature about percutaneous radio frequency (RF) ablation or, in particular, high‐intensity focused ultrasonography (HIFU) for the treatment of RCC in a graft kidney. In the case report described by Chakera, the HIFU approach was only an attempt prior to surgery, and there was not a complete necrosis; for these reasons, our study is unique with regard to the intention to use this treatment.…”

mentioning

confidence: 99%

High‐Intensity Focused Ultrasonography and Radiofrequency Ablation of Renal Cell Carcinoma Arisen in Transplanted Kidneys: Single‐Center Experience With Long‐Term Follow‐Up and Review of Literature

Candio

Porcelli

Campatelli

et al. 2019

J of Ultrasound Medicine

View full text Add to dashboard Cite

The purpose of this article is to retrospectively evaluate the long‐term outcome of patients treated with percutaneous thermoablation for renal cell carcinomas that have arisen in kidney grafts. Between April 2008 and February 2011, we treated 3 patients with renal cell carcinoma on a transplanted kidney: 2 cases were treated with high‐intensity focused ultrasonography and 1 patient with radio frequency ablation. Postprocedural ultrasonography did not reveal any complications, and contrast‐enhanced ultrasonography showed an avascular area in the treated nodules. None of the patients had recurrent tumors during a long‐term clinical and radiologic follow‐up (81, 73, and 43 months, respectively).

show abstract

Donor Kidney With Renal Cell Carcinoma Successfully Treated With Radiofrequency Ablation: A Case Report

Cited by 9 publications

References 15 publications

Thermoablative Treatment of De Novo Tumor in Kidney Allograft

Thermoablative Treatment of De Novo Tumor in Kidney Allograft

Systematic review of ablative therapy for the treatment of renal allograft neoplasms

High‐Intensity Focused Ultrasonography and Radiofrequency Ablation of Renal Cell Carcinoma Arisen in Transplanted Kidneys: Single‐Center Experience With Long‐Term Follow‐Up and Review of Literature

Contact Info

Product

Resources

About